[en] HIGHLIGHTS • People living with HIV show similar humoral immune responses towards the third dose of SARS-CoV-2 vaccine compared to HIV-negative individuals. • People living with HIV with no prior SARS-CoV-2 infection show reduced T-cell response towards the third dose of SARS-CoV-2 vaccine compared to HIV-negative individuals. • Hybrid immunity induces similar T-cell responses between people living with HIV and HIV-negative individuals. The full-text article is available free by clicking the following link: https://www.journalofinfection.com/article/S0163-4453(22)00534-5/fulltext
Immunology & infectious disease
Author, co-author :
El Moussaoui, Majdouline ; Université de Liège - ULiège > Département des sciences cliniques > Immunopathologie - Maladies infectieuses et médecine interne générale
Desmecht, Salomé ; Université de Liège - ULiège > Département des maladies infectieuses et parasitaires (DMI)
Hagiya, H., Hikita, T., Habu, T., Asada, M., Yorifuji, T., Toyooka, S., et al. Poor vaccine responsiveness towards third-dose mRNA vaccine of COVID-19 in Japanese older people. J Infect, S0163-4453(22), 2022, 00413, 10.1016/j.jinf.2022.07.007 -3.
Boffito, M., Waters, L., More evidence for worse COVID-19 outcomes in people with HIV. Lancet HIV 8:11 (2021), e661–e662, 10.1016/S2352-3018(21)00272-1.
Hassold, N., Brichler, S., Ouedraogo, E., Leclerc, D., Carroue, S., Gater, Y., et al. Impaired antibody response to COVID-19 vaccination in advanced HIV infection. AIDS 36:4 (2022), F1–F5, 10.1097/QAD.0000000000003166.
Lapointe, H.R., Mwimanzi, F., Cheung, P.K., Sang, Y., Yaseen, F., Umviligihozo, G., et al. People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses. J Infect Dis, 2022, jiac229, 10.1093/infdis/jiac229.
Tau, L., Turner, D., Adler, A., Marom, R., Ahsanov, S., Matus, N., et al. SARS-CoV-2 humoral and cellular immune responses of patients with HIV after vaccination with BNT162b2 mRNA COVID-19 vaccine in the Tel-Aviv medical center. Open Forum Infect Dis, 9(4), 2022, ofac089, 10.1093/ofid/ofac0896 Published 2022 Feb 23.
Antinori, A., Cicalini, S., Meschi, S., Bordoni, V., Lorenzini, P., Vergori, A., et al. Humoral and cellular immune response elicited by mRNA vaccination against SARS-CoV-2 in people living with HIV (PLWH) receiving antiretroviral therapy (ART) according with current CD4 T-lymphocyte count [published online ahead of print, 2022 Apr 2]. Clin Infect Dis, 2022, ciac238, 10.1093/cid/ciac238.
Brumme, Z.L., Mwimanzi, F., Lapointe, H.R., Cheung, P.K., Sang, Y., Duncan, M.C., et al. Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. NPJ Vaccines, 7, 2022, 28, 10.1038/s41541-022-00452-6.
Evans, J.P., Zeng, C., Carlin, C., Lozanski, G., Saif, L.J., Oltz, E.M., et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci Transl Med, 14(637), 2022, eabn8057, 10.1126/scitranslmed.abn805710.
Ogbe, A., Pace, M., Bittaye, M., Tipoe, T., Adele, S., Alagaratnam, J., et al. Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight, 7(7), 2022, e157031, 10.1172/jci.insight.157031.